How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursive self-improvement AI now has a co-evolving evaluator: a Cambridge and NVIDIA preprint introduces the Red Queen Gödel ...

The compiler infers, but does not take instructions. There is no syntax for explicit type declarations yet, and the new type ...

Ben Taylor, CFO of Recursion, here with us. Thanks so much for joining us. Sure. Great. And first of all, thanks for having us here, Tommie. This is always a terrific conference and great to be here.

Buy: Anthropic exposure via its likely IPO/secondary path (e.g., IPO allocation or liquid proxy like AI-safety/compute beneficiaries). Rationale: Anthropic is pushing “slow/pause” policy while still ...

One of the key challenges of current multi-agent AI systems is that they communicate by generating and sharing text sequences, which introduces latency, drives up token costs, and makes it difficult ...

Lets geek out. The HackerNoon library is now ranked by reading time created. Start learning by what others read most. Lets geek out. The HackerNoon library is now ranked by reading time created. Start ...

Penn Engineers have developed a new way to use AI to solve inverse partial differential equations (PDEs), a particularly challenging class of mathematical problems with broad implications for ...

Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...

Welcome everybody to Recursion's Earnings Call. I'm Chris Gibson, Co-Founder and CEO, and I'm excited to take you through Recursions 2024, 2025 and the time ahead. So with that we'll jump into the ...